Develop RNA interference therapeutics for the treatment of intractable diseases. Focus on liver diseases, hypertriglyceridemia, and genetic disorders. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 56% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Sales are growing strongly for its sector.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 56% a year on average.
The company sells $829.4M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $1.6M against $829.4M in annual sales.
Over the last 12 months, executives reported 77 sells against just 14 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, ARWR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ARWR has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (43/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.